Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on Legend Biotech and increased the price target from $48 to $49. This indicates a continued positive outlook from the analyst, suggesting potential upside for the stock, albeit a modest increase in the target price.
Morgan Stanley analyst Matthew Harrison has maintained an 'Overweight' rating on Legend Biotech (LEGN) and slightly raised the price target from $48 to $49. This action signals continued confidence from a major investment bank in the company's prospects. While the price target increase is modest, it reinforces the analyst's positive stance, which could provide a short-term boost to investor sentiment and potentially the stock price. For traders, this indicates a continued bullish outlook from a reputable source, suggesting an opportunity for long positions, though the small target increase might temper significant immediate upward movement. The long-term implication is a sustained positive view on the company's fundamentals by this analyst.